Glycosaminoglycan Therapy for Bladder Diseases: Emerging New Treatments

European Urology, Supplements

Volumn 10, Issue 6, 2011, Pages 451-459

  Bassi, Pier Francesco ^a   Costantini, Elisabetta ^b   Foley, Steve ^c   Palea, Stefano ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^d Urosphere SAS   (France)

Author keywords

Chronic cystitis; Ialuril; Intravesical instillation; Painful bladder syndrome; Sodium hyaluronate chondroitin sulfate

Indexed keywords

CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HISTAMINE; HYALURONIC ACID; IALURIL; PLACEBO; UNCLASSIFIED DRUG;

BLADDER CANCER; BLADDER COMPLIANCE; BLADDER DISEASE; BLADDER DYSFUNCTION; BLADDER STONE; BLADDER WALL; CELL ACTIVATION; CHEMICAL CYSTITIS; CLINICAL TRIAL (TOPIC); CYSTALGIA; DISEASE SEVERITY; HISTAMINE RELEASE; HUMAN; HYPERSENSITIVITY; INTERSTITIAL CYSTITIS; MAST CELL; NEUROGENIC INFLAMMATION; NONHUMAN; OVERACTIVE BLADDER; PAINFUL BLADDER SYNDROME; PATHOGENESIS; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOOTH MUSCLE CONTRACTION; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINARY URGENCY; UROTHELIUM;

EID: 80052146065     PISSN: 15699056     EISSN: 18781500     Source Type: Journal    
DOI: 10.1016/j.eursup.2011.06.001     Document Type: Review

References (37)

1. Fall M., Oberpenning F., Peeker R. Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions?. Eur Urol 2008, 54:65-78.
2. Cervigni M., Natale F., Nasta L., Padoa A., Voi R.L., Porru D. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:943-947.
3. Iavazzo C., Athanasiou S., Pitsouni E., Falagas M.E. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis?. Eur Urol 2007, 51:1534-1541. discussion 1540-1.
4. Parsons C.L. The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU Int 2011, 107:370-375.
5. Costantini E. The role of the urinary epithelium. Presentation at: 26th Annual European Association of Urology Congress; March 18-21 2011.
6. Riedl C.R., Engelhardt P.F., Daha K.L., et al. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:717-721.
7. Marchand J.E., Sant G.R., Kream R.M. Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis. Br J Urol 1998, 81:224-228.
8. Sant G.R., Kempuraj D., Marchand J.E., Theoharides T.C. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007, 69:34-40.
9. Hurst R.E., Parsons C.L., Roy J.B., Young J.L. Urinary glycosaminoglycan excretion as a laboratory marker in the diagnosis of interstitial cystitis. J Urol 1993, 149:31-35.
10. Keay S., Warren J.W., Zhang C.O., et al. Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients. J Urol 1999, 162:1487-1489.
11. Keay S., Zhang C.O., Marvel R., Chai T. Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor: sensitive and specific urine markers for interstitial cystitis. Urology 2001, 57(Suppl 1):104.
12. Rastogi P., Rickard A., Dorokhov N., Klumpp D.J., McHowat J. Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders. Am J Physiol Renal Physiol 2008, 294:F1129-F1135.
13. Alagiri M., Chottiner S., Ratner V., Slade D., Hanno P.M. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 1997, 49:52-57.
14. Aaron L.A., Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001, 134:868-881.
15. Clauw D.J. The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Med Hypotheses 1995, 44:369-378.
16. Sand P.K. Proposed pathogenesis of painful bladder syndrome/interstitial cystitis. J Reprod Med 2006, 51:234-240.
17. Sant G.R. Etiology, pathogenesis, and diagnosis of interstitial cystitis. Rev Urol 2002, 4(Suppl 1):S9-15.
18. van de Merwe J.P., Nordling J., Bouchelouche P., et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008, 53:60-67.
19. Wesselmann U. Interstitial cystitis: a chronic visceral pain syndrome. Urology 2001, 57(Suppl 1):32-39.
20. Jasmin L., Janni G., Manz H.J., Rabkin S.D. Activation for CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation. J Neurosci 1998, 18:10016-10029.
21. Nazif O., Teichman J.M., Gebhart G.F. Neural upregulation in interstitial cystitis. Urology 2007, 69:24-33.
22. Chuang Y.C., Chancellor M.B., Seki S., et al. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology 2003, 61:664-670.
23. Parsons C.L. Prostatitis, interstitial cystitis, chronic pelvic pain, and urethral syndrome share a common pathophysiology: lower urinary dysfunctional epithelium and potassium recycling. Urology 2003, 62:976-982.
24. Saĝlam B., Cikler E., Zeybek A., Çetinel S., Ercan F., Şener G. Protective effects of 2-mercaptoethane sulfonate (mesna) on protamine sulfate induced bladder damage. Marmara Med J 2005, 18:6-12.
25. Palea S. Experimental effects of sodium hyaluronate and chondroitin sulfate combination in a bladder model. Presentation at: 26th Annual European Association of Urology Congress; March 18-21 2011.
26. Füllhase C., Soler F., Gratzke C., Brodsky M., Christ G.J., Andersson K.-E. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. J Urol 2010, 184:783-789.
27. De Laet K., DeWachter S., Wyndaele J.-J. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006, 25:156-161.
28. Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 2010, 29:112-115.
29. Parsons C.L. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 2007, 69:9-16.
30. Bassi P.F. Insights on clinical use of Ialuril®. Presentation at: 26th Annual European Association of Urology Congress; March 18-21 2011.
31. Parsons C.L. A model for the function of glycosaminoglycans in the urinary tract. World J Urol 1994, 12:38-42.
32. Damiano R., Quarto G., Bava I., et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 2011, 59:645-651. Corrigendum. Eur Urol 2011;60:193.
33. McLean R.J., Nickel J.C. Glycosaminoglycans and struvite calculi. World J Urol 1994, 12:49-51.
34. Siracusano S., Cucchi A., Ciciliato S., Lampropoulou N., Vittur F. Urinary levels of glycosaminoglycans in patients with idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2009, 20:1477-1480.
35. Chen S.C., Henry D.O., Hicks D.G., Reczek P.R., Wong M.K. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol 2009, 181:336-342.
36. Huygens A., Crnolatac I., Maes J., et al. Influence of the glycosaminoglycan layer on the permeation of hypericin in rat bladders in vivo. BJU Int 2007, 100:1176-1181.
37. Foley S. Management of bladder dysfunctions in UK: Ialuril® in clinical practice. Presentation at: 26th Annual European Association of Urology Congress; March 18-21 2011.